Weaning patients with less-potent topical corticosteroids (10/0 hydrocortisone or desonide cream) or topical calcineurin inhibitors (1% pimecrolimus) may minimize flares (Oppel, Pavicic ...

and mupirocin ointment. Patch testing with the North American Contact Dermatitis Group (NACDG) standard tray, corticosteroids, vehicles, preservatives, flavorings, corticosteroids, cosmetics ...

Medically reviewed by Jurairat J. Molina, MD Dermatitis is a group of skin problems related to genes, environment, and ...

The US FDA has approved Vtama 1% cream for the topical treatment of atopic dermatitis in adult and pediatric patients aged 2 ...

People with eczema usually experience flare-ups during the winter season. During these periods, symptoms become worse and ...

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis. Ahead of its extended target action date of March 12, 2025, the FDA approved ...

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative ...

“With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there is now a therapy that offers the potential for powerful skin clearance with ...

More patients treated with Vtama achieved vIGA-AD success compared with those who received vehicle cream in both ADORING 1 (45% vs 14%) and ADORING 2 (46% vs 18%). The Food and Drug Administration ...

Technoderma Medicines, Inc. ('the Company'), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ...

CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis: San Carlos, California Saturday, January 11, 20 ...